Under the category of the OTC/Nutraceutical products are listed the products which are sold without prescription. Members of Farmavita.net are invited to publish their out-license offers in this Category.

Ropinirole HCl

Popular

Description

There is on-going development of generic  EU CTD Dossier of Ropinirole HCl, filmcoated tablets, 0.25/0.5/1/2 mg.

Development of this pharmaceutical is carried out according to EU-requirements in country without patent protection or with Bolar-provisions. There will be no sales in those countries where this offer would constitute an infringement of third parties intellectual proprietary rights.

Ropinirole (Requip, Ropark, Adartrel) is a non-ergoline dopamine agonist. It is manufactured by GlaxoSmithKline (GSK) and Sun Pharmaceutical. It is used in the treatment of Parkinson's disease. Ropinirole is also one of two medications in the United States (U.S.) with an Food and Drug Administration (FDA) approved indication for the treatment of restless legs syndrome (RLS), the other being pramipexole (Mirapex). The discovery of the drug's utility in RLS has been used as a successful example of drug repurposing.

Ropinirole's patent expired in May 2008, and the drug is now available in generic form.

More details at: http://www.rxlist.com/requip-drug.htm.

More details

Name Description
Pharma licensing Out-licensing (offer)

Ad details

Ad ID : 589

Advertiser details

Contact Advertiser

Add comment

 
 

Contact form

Sorry, you need to register or login first.

What's wrong with this ad?

Sorry, you need to register or login first.

Add to favourites

Sorry, you need to register or login first.

Advert search

Recent adverts

Lokking for EU CTD Dossiers for traditional...
546 Views
Member of  Farmavita.Net from EU is looking to...
5452 Views
We are looking to acquire Azathioprine tablet...
5855 Views
I am looking for a good quality dossier with...
6592 Views
We offer for outlicensing European e-CTD...
9797 Views
Novel herbal based throat pastilles with...
1852 Views
We are looking for EU-CTD dossier...
8119 Views